Results about: mitofusin 2
A project headed by Antonio Zorzano at IRB Barcelona has been awarded funding from the BBVA Foundation to explore a possible link between ageing and cancer.
Called MitoFuss, the project focuses on the mitochondrial protein Mitofusin 2.
Researchers discover activators of a potential therapeutic target for the treatment of patients with diabetes and insulin resistance
A team headed by Antonio Zorzano at IRB Barcelona has identified activators of the mitochondrial protein Mitofusin 2 for the treatment of type 2 diabetes.
The protein is a key regulator of many mitochondrial functions, as well as of the cell as a whole.
IRB Barcelona researchers discover that the loss of the protein Mitofusin 2 in the muscles of young mice speeds up aging and causes early sarcopenia, thus leading to the muscle quality of aged mice.
Sarcopenia, which is muscle wastage and the accompanied loss of strength, is one of the most weakening conditions of old age and it has no treatment.
The scientists propose that stimulating Mitofusin 2 activity would provide a good strategy through which to ameliorate sarcopenia.